Introduction
============

Tuberculosis remains a considerable global public health concern with over nine million cases and 1.7 million deaths notified to the World Health Organization in 2006.[@ref1] Considerable progress has been made towards achieving the millennium development goals for tuberculosis by 2015, with incidence rates declining in the past two years.[@ref1] Central to the recommended treatment strategy is the use of directly observed treatment to ensure adherence. Intermittent or incomplete treatment has been associated with adverse outcomes for patients (severe disease and long term disability, low cure rate, disease relapse, or even death) and for public health (prolonged infectiousness and transmissibility and the development of drug resistance).

A series of Cochrane reviews are examining various methods of enhancing adherence to tuberculosis treatment. One review concluded that randomised trials provide no evidence that directly observed treatment improves cure or rates of completion of treatment in low and middle income countries compared with self administered treatment.[@ref2] Reminder systems and late patient tracers are effective in various settings, although most trials have been conducted in high income countries.[@ref3] The provision of monetary and other incentives to improve treatment adherence, including the provision of cash payments and food vouchers, has been found to be effective in some settings.[@ref4]

Food incentives are attractive because of the well described link between malnutrition and tuberculosis; malnourished adults are more likely to develop tuberculosis and tuberculosis causes weight loss.[@ref5] The extent of malnutrition at diagnosis is strongly associated with severity of lung disease, increased relapse rates, and mortality in adults with pulmonary tuberculosis.[@ref6] [@ref7] [@ref8] Specifically, Khan and colleagues have shown that patients with tuberculosis who are underweight at diagnosis and achieve a weight gain of less than 5% during the intensive phase of treatment are at higher risk of disease relapse during the following two years.[@ref8]

Various nutritional supplements are being used in tuberculosis programmes in many settings and have been advocated by the World Food Program.[@ref9] Nutritional supplements are popular with patients,[@ref10] but a recent Cochrane review showed unconvincing evidence of a direct benefit of food supplements on a range of clinical outcomes.[@ref11]

We investigated whether nutritional supplementation with culturally appropriate food is an effective adjunctive therapy to enhance completion of tuberculosis treatment in Timor-Leste.

Methods
=======

Setting
-------

Timor-Leste is a small, newly independent Asian country with a population of around a million and a gross domestic product of \$364 (£229, €244) per person per annum.[@ref12] It has a high incidence of tuberculosis but low rates of HIV and drug resistance.[@ref13] There is a well functioning National TB Control Program (NTP), which uses the WHO strategy known as DOTS (directly observed treatment).[@ref14] The study was conducted in three community clinics in the capital city, Dili. The clinics were government, private, and church operated (one of each) and covered geographically distinct zones within the city. Enrolment started on 16 March and was completed on 9 November 2005, with follow-up of all patients completed by July 2006. A political crisis starting on 28 April 2006 led to civil conflict in Dili for several months, including disruption to delivery of health services and the displacement of an estimated 70% of Dili's population to camps within the city or to the rural districts.[@ref15]

Participants and procedures
---------------------------

The study sample consisted of patients with newly diagnosed pulmonary tuberculosis (positive and negative results on sputum smear tests). A nurse or physician examined all outpatients and referred those with possible tuberculosis to the tuberculosis nurse for further examination, including sputum collection (spot/morning/spot). Trained laboratory technicians examined sputum by using the standard Ziehl-Neelsen method on direct smears. The diagnosis of tuberculosis in patients with negative smear results conformed to the NTP guidelines (no clinical response to 14 days' treatment with broad spectrum antibiotics and chest x ray picture suggestive of active tuberculosis). The WHO reference laboratory in Adelaide, Australia, provided quality control of the tuberculosis laboratories. All participants received routine care, including drugs, default tracing, and clinical monitoring according to the NTP guidelines. Patients with tuberculosis were eligible for inclusion if they were aged ≥18 and agreed to receive tuberculosis treatment at the diagnosing clinic for eight months. Exclusion criteria were pregnancy and previous treatment for tuberculosis for more than one month.

Patients were asked to attend the clinic according to routine practice (five or six mornings a week) to receive directly observed treatment (intensive phase with daily rifampicin, isoniazid, pyrazinamide, and ethambutol daily for two months, followed by a continuation phase with isoniazid and ethambutol daily for six months) in appropriate doses (see table A on bmj.com). Treatment was administered fortnightly in the continuation phase.

Randomisation and blinding
--------------------------

At each study site a research assistant randomly allocated study participants to the intervention group (supplementary food) or control group (nutritional advice). An independent statistician computer generated a random allocation sequence with randomly varying block sizes in Stata (version 8). The sequence was concealed from all investigators with sequentially numbered opaque sealed envelopes prepared distant from the study site. Allocation was stratified by community health clinic and by diagnosis of tuberculosis (smear positive and smear negative). Both participants and treatment providers were aware of an individual's allocation status after randomisation. An independent observer (PM, based in Darwin), who was blinded to the intervention received by the patients, however, determined the primary outcome (treatment completion).

Study intervention
------------------

At enrolment, the research assistant gave patients randomised to nutritional advice (control group) verbal and written advice concerning the types of locally available food that would constitute a balanced diet likely to assist cure of tuberculosis. These patients received routine care and were asked to attend the clinic at the usual time (early morning).

Patients in the intervention group were asked to attend the clinic at mid-day. In addition to usual treatment for tuberculosis, they received food every time they attended the clinic. In the intensive phase, each day they were provided with one bowl of feijuada, a locally popular meat, red kidney beans, and vegetable stew with rice, at the clinic (table 1[](#tbl1){ref-type="table"} and table B on bmj.com). This meal was rich in energy, protein, and micronutrients.[@ref16] The ingredients were obtained from local suppliers with fresh produce bought on the day of consumption and other produce bought in bulk. In the intensive phase of treatment a research assistant directly observed food intake. During the continuation phase of treatment, patients were given a food parcel containing unprepared food to take home (red kidney beans, rice, and oil). The quantities were calculated to provide one meal a day for one adult. At random intervals during the study period two authors (NM and PMK) checked the quality and quantity of produce. An independent assessment was carried out to ensure the safe preparation and administration of the intensive phase intervention.

###### 

 Estimated nutritional value of average serving size for daily meal consumed by patients in intervention group in intensive phase of treatment

  Nutrient           Quantity   %RDI^16^   
  ------------------ ---------- ---------- ----
  Energy (kJ)        1800       24         25
  Protein (g)        18.4       34         48
  Carbohydrate (g)   55.6       17         17
  Vitamin C (mg)     24.2       63         64
  Vitamin A (μg)     363        47         62
  Iron (mg)          3.1        45         21
  Zinc (mg)          3          25         45
  Folate (μg)        60         18         18

RDI=recommended daily intake.

Outcome measures
----------------

We used standard Timorese NTP definitions of treatment outcome (see table C on bmj.com). The primary outcome measure was completion of treatment (clearance of acid fast bacilli from the sputum after treatment or the completion of eight months of treatment, or both). Secondary outcome measures were adherence to treatment, clinical improvement, and adverse events. Adherence was measured by recording clinic attendance and directly observed treatment (daily in the intensive phase and fortnightly in the continuation phase) and through interview and pill counts (in the continuation phase). All other measurements were performed weekly during the intensive phase and fortnightly during the continuation phase of treatment. Clinical improvement was measured by recorded clinical symptoms and weight gain. Percentage of weight change was calculated as the difference in weight at two times (for example, diagnosis and eight weeks) divided by the weight at the earlier time, multiplied by 100. Adverse events were actively recorded with a standardised questionnaire.

Sample size
-----------

Based on existing default rates of 13%, we calculated that we needed to enrol 270 patients to detect a reduction in the primary outcome (default rate) to an acceptable 3%, with 80% power and an α of 0.05.

Statistical analysis
--------------------

Analysis was by intention to treat. We used independent *t* tests and Kruskal-Wallis tests to compare the difference in continuous variables between groups and Pearson's χ^2^ test to compare the association between treatment group and categorical variables. Relative risks with 95% confidence intervals were calculated with standard methods. Rates of completion of treatment and clinical outcomes were also analysed with logistic regression with adjustment for prespecified confounding factors. Kaplan-Meier survival estimates were used to examine the relation between the intervention and time to default. Significance was based on a two tailed P\<0.05. Analysis of secondary outcomes was regarded as "hypothesis generating." No adjustment was made for multiple comparisons. All statistical analyses were performed with Stata (version 9.1).

Results
=======

During the study enrolment period tuberculosis was diagnosed in 833 patients at the three clinics in Dili. Of these, 270 patients were recruited into the study (fig 1[](#fig1){ref-type="fig"}). All participants received the allocated intervention, and only five (1.9%) were transferred to other clinics and did not contribute a primary outcome.

![**Fig 1** Flow of participants through study. Original sample included all diagnoses of tuberculosis in three clinics during study period, March 2005 to July 2006. Ineligible patients included 62 (25%) previously treated for tuberculosis, 176 (72%) aged \<18, and 7 (3%) pregnant women. Others excluded, according to selection criteria, included 211 (79%) transferred out before enrolment, 42 (16%) community directly observed treatment (clinician's decision), 7 (3%) unable to agree to complete treatment, 5 (2%) default before enrolment, 1 (0.5%) died before enrolment. Refusals: 43 (83%) unwilling to attend for midday meal; 9 (17%) chose community DOT (unable to attend clinic, self assessed disease severity). Loss to follow-up means transferred out to another clinic during treatment](marn670190.f1_default){#fig1}

After randomisation, the two groups of patients had similar demographic characteristics (table 2[](#tbl2){ref-type="table"}). Most enrolled patients were young (mean age 33.3), male (175/270, 65%), poor (209/261 (80%) had no formal income), and lived close to the clinic (mean distance 2.4 km). Enrolled patients had had symptoms of tuberculosis for a mean of eight weeks before their diagnosis. There were no significant differences in the nature, duration, or frequency of tuberculosis symptoms or healthcare seeking behaviour between the two groups. Most patients (213/268, 80%) were malnourished, with almost one in three in WHO's severely malnourished range (body mass index (BMI) \<16.0).[@ref17] A relatively small proportion (79/270, 29%) of patients had positive results on sputum smear tests; this was similar in both groups and consistent with previous studies in Timor-Leste.[@ref14]

###### 

 Baseline characteristics of study participants. Figures are numbers (percentages) unless stated otherwise\*

                                              Control (n=133)   Intervention (n=137)   Total (n=270)
  ------------------------------------------- ----------------- ---------------------- ---------------
  **Demographic characteristics**                                                      
  Mean (SD) age (years)                       32.6 (13.4)       33.9 (14.2)            33.3 (13.8)
  Male                                        86 (65)           89 (65)                175 (65)
  Unemployed                                  60 (45)           56 (41)                116 (43)
  Income (\$/month):                                                                   
   0                                          103 (80)          106 (80)               209 (80)
   1-100                                      10 (8)            19 (14)                29 (11)
   \>100                                      15 (12)           8 (6)                  23 (9)
  Mean (SD) distance to clinic (km)           2.4 (1.8)         2.4 (1.4)              2.4 (1.6)
  **Clinical characteristics**                                                         
  Median (IQR) duration of illness (weeks)†   8 (4-28)          8 (4-20)               8 (4-24)
  BMI:                                                                                 
   \<16.0                                     40 (30)           44 (32)                84 (31)
   16.0-16.9                                  30 (23)           33 (24)                63 (24)
   17.0-18.4                                  35 (27)           31 (23)                66 (25)
   \>18.5                                     27 (20)           28 (21)                55 (20)
  Mean (SD) weight (kg)                       43.6 (7.6)        43.0 (7.3)             43.3 (7.5)
  Smear positive                              38 (29)           41 (30)                79 (29)

IQR=interquartile range; BMI=body mass index.

\*Data missing for age (1 intervention), income (5 control, 4 intervention), distance to clinic (7 control, 6 intervention), duration of illness (2 controls), BMI (1 control, 1 intervention).

†Kruskal-Wallis test.

For the primary outcome of completion of treatment, there was no significant difference between the intervention (100/129, 76%) and control (103/136, 78%) groups (relative risk 0.98, 95% confidence interval 0.86 to 1.11) (table 3[](#tbl3){ref-type="table"}). This is equivalent to a risk difference of −2% (−11% to 9%). In patients with positive smear results, there was a non-significant difference in completion of treatment (31/40, 78% for the intervention group *v* 25/37, 68% for controls, 1.15, 0.87 to 1.52; see table 4[](#tbl4){ref-type="table"}). The civil conflict dramatically increased the default rate of those patients (68, 25%) still receiving treatment after 28 April 2006 and led to a significant decrease in treatment completion (168/199 (84%) before conflict *v* 35/66 (53%) after conflict; 1.58, 1.26 to 2.01; P\<0.001).

###### 

 Primary and secondary outcomes and adverse events by intention to treat analysis in all patients\*. Figures are numbers (percentages) unless stated otherwise

  Outcome                    Control (n=129)   Intervention (n=136)   RR/mean difference† (95% CI, P value)
  -------------------------- ----------------- ---------------------- ---------------------------------------
  **Primary outcome**                                                 
  Treatment success                                                   
   Overall                   100 (78)          103 (76)               0.98 (0.86 to 1.11, 0.7)
   Before conflict           82 (85)           86 (84)                1.0 (0.88 to 1.12, 1.0)
   After conflict            18 (56)           17 (50)                0.89 (0.56 to 1.40, 0.6)
  **Secondary outcomes**                                              
  Mean % (SD) compliance:                                             
   Intensive                 91.4 (13.3)       86.7 (18.6)            −4.7 (−0.8 to −8.6, 0.02)
   Continuation              98.3 (6.7)        98.2 (6.7)             0 (−1.7 to 1.7, 1.0)
  Mean % (SD) weight gain:                                            
   8 weeks                   3.5 (6.3)         5.2 (6.2)              1.7 (0.1 to 3.2, 0.04)
   32 weeks                  7.5 (7.6)         10.1 (9.6)             2.6 (0.1 to 5.1, 0.04)
  Cough clearance:                                                    
   4 weeks                   54 (42)           52 (43)                1.02 (0.76 to 1.36, 0.9)
   8 weeks                   60 (61)           57 (58)                0.94 (0.75 to 1.18, 0.6)
   32 weeks                  76 (80)           80 (84)                1.05 (0.92 to 1.20, 0.4)
  Adverse events:                                                     
   Itch                      12 (9)            28 (21)                2.27 (1.20 to 4.26, 0.008)

\*Data missing for success (4 control and 1 intervention); compliance (1 control in intensive phase, 13 control and 14 intervention in continuation phase); weight (11 control and 16 intervention at 8 weeks, 42 control and 40 intervention at 32 weeks); cough (3 control and 14 intervention at 4 weeks, 35 control and 38 intervention at 8 weeks, 38 control and 42 intervention at 32 weeks).

†Relative risk for comparisons of categorical variables or mean difference for comparisons of means of continuous variables.

###### 

 Primary and secondary outcomes and adverse events by intention to treat analysis in patients with positive sputum smear results\*. Figures are numbers (percentages) unless stated otherwise

  Outcome                    Control (n=37)   Intervention (n=40)   RR/mean difference† (95% CI, P value)
  -------------------------- ---------------- --------------------- ---------------------------------------
  **Primary outcome**                                               
  Treatment success:                                                
   Overall                   25 (68)          31 (78)               1.15 (0.87 to 1.52, 0.3)
   Before conflict           24 (77)          29 (91)               1.17 (0.94 to 1.46, 0.2)
   After conflict            1 (17)           2 (25)                1.5 (0.17 to 12.9, 0.7)
  **Secondary outcomes**                                            
  Clearance at 4 weeks       18 (67)          22 (85)               1.27 (0.92 to 1.74, 0.13)
  Mean % (SD) compliance:                                           
   Intensive                 93.5 (8.2)       89.9 (18.7)           −3.6 (−10.2 to 3.1, 0.3 )
   Continuation              97.1 (9.7)       96.8 (10.3)           −0.4 (−5.0 to 4.3, 0.9)
  Mean % (SD) weight gain:                                          
   8 weeks                   5.9 (8.0)        6.6 (7.8)             0.6 (−3.0 to 4.3, 0.7)
   32 weeks                  11.7 (9.0)       13.8 (13.1)           2.1 (−3.9 to 8.2, 0.5)
  Cough clearance:                                                  
   4 weeks                   17 (46)          16 (43)               0.94 (0.57 to 1.56, 0.8)
   8 weeks                   19 (63)          21 (62)               0.97 (0.67 to 1.43, 0.9)
   32 weeks                  19 (83)          25 (86)               1.04 (0.82 to 1.32, 0.7)
  Adverse events:                                                   
  Itch                       1 (3)            12 (30)               11.1 (1.51 to 81.5, 0.01)

\*Data missing for success (1 control and 1 intervention); sputum clearance (11 control and 15 intervention; compliance (1 control in intensive phase, 3 control and 4 intervention in continuation phase); weight (1 control and 3 intervention at 8 weeks, 12 control and 14 intervention at 32 weeks); cough (1 control and 4 intervention at 4 weeks, 8 control and 7 intervention at 8 weeks, 15 control and 12 intervention at 32 weeks).

†Relative risk for comparisons of categorical variables or mean difference for comparisons of means of continuous variables.

Secondary outcomes included adherence to treatment, weight gain, symptomatic improvement in all patients, and sputum smear clearance in the subgroup with positive smear test results. Almost all non-completion was because of default from treatment: there was only one death and one treatment failure during the study (see table C on bmj.com for definitions). While the default rate was higher than expected, most of this occurred in the final weeks of treatment. Early default was rare (fig 2[](#fig2){ref-type="fig"}). Over half of the defaults were associated with the civil conflict (31/60). The intervention had no significant effect on default rates or time to default. While participants were receiving treatment, adherence was high, particularly in the continuation phase (98%). In the intensive phase, adherence was significantly lower in the intervention group (86.7%) than in the control groups (91.4%, P=0.02).

![**Fig 2** Kaplan-Meier plot showing time to default by group. Hazard ratio for time to default 1.10 (0.66 to 1.82), P=0.7. Not significantly influenced by age, sex, or result of smear test](marn670190.f2_default){#fig2}

The provision of tuberculosis treatment rapidly alleviated or considerably reduced most of the baseline symptoms. Haemoptysis and fever virtually disappeared during the first two months of treatment. Cough remained in most patients after four weeks and in a significant minority after eight weeks of treatment (table 3 and fig 3[](#tbl3){ref-type="table"} [](#fig3){ref-type="fig"}). The food intervention did not significantly hasten improvement in symptoms. Weight gain was significantly greater in the intervention group, both at the end of the intensive phase (5.2% increase for intervention *v* 3.5% for controls, P=0.04) and at the end of treatment (10.1% *v* 7.5%, P=0.04) (table 3[](#tbl3){ref-type="table"} and fig 4[](#fig4){ref-type="fig"}). This relation was less strong in the subgroup with positive sputum smear results. In a post hoc analysis of those who were underweight at baseline (BMI \<18.5, n=209 with 18 missing values), the food intervention led to a significant likelihood of adequate weight gain (that is, more than 5%) at two months compared with the control group (66/110 (60%) for the intervention group *v* 31/82 (38%) for controls; crude odds ratio 2.47, 1.37 to 4.44; P=0.003). After adjustment for age, sex, height, and smear result, the adjusted odds ratio was 2.69 (1.44 to 5.00; P=0.002). The result was even more striking in the subgroup who were severely underweight (BMI \<16.0: 22/39 (56%) in intervention group *v* 10/38 (26%) controls), in whom the crude odds ratio was 3.62 (1.39 to 9.47; P=0.009) and the adjusted odds ratio was 3.37 (1.25 to 9.10; P=0.02).

![**Fig 3** Cough clearance in patients with tuberculosis](marn670190.f3_default){#fig3}

![**Fig 4** Weight gain in patients with tuberculosis](marn670190.f4_default){#fig4}

In patients with positive sputum smear results, there was a non-significant improvement in sputum clearance at one month (18% absolute improvement, P=0.13). For this analysis, there was a substantial number of missing values because of default, refusal, inability to cough, or laboratory error. Patients with missing data, however, were similar at baseline when compared with those who were included in the analysis.

Over half the participants reported at least one adverse event potentially attributable to tuberculosis treatment. These were minor adverse events that occurred mostly during the first week of treatment and resolved with symptomatic treatment. None of the patients had to stop treatment. The main complaints were influenza syndrome, itch, and nausea. Itch with or without rash was more than twice as likely to occur in the intervention group (table 3).[](#tbl3){ref-type="table"} In patients with positive sputum smear results, the association was even more striking (relative risk 11.1, 1.51 to 81.5).

Multivariate analyses with adjustment for sputum smear result, clinic type, sex, education, occupation, income, and distance from the clinic did not change the results for outcome measures or adverse events.

Discussion
==========

In this randomised controlled trial to examine the use of food as an incentive to improve outcome with tuberculosis treatment we found that food incentives led to modestly higher weight gain but did not result in a significant improvement in adherence to treatment or successful completion of treatment. Substantial improvement in completion of treatment (≥10%) is unlikely in this setting. Smaller beneficial (or harmful) effects cannot be excluded.

Our participants adhered well to treatment, and food, though expensive, was readily available at the urban study site during most of the study period. In other settings---for example, in sub-Saharan Africa where treatment completion rates are generally lower[@ref1] and food insecurity is widespread[@ref18]---the result might be different.

Conflicting evidence of effectiveness in previous trials
--------------------------------------------------------

The influence of macronutrient or micronutrient supplementation on outcomes of tuberculosis treatment has been inconclusive in the limited number of trials reported to date and has been summarised in a recent Cochrane review[@ref11] and in table 5[](#tbl5){ref-type="table"}. Reported outcome measures have included sputum smear clearance, symptomatic improvement, weight gain during treatment, cure, recurrence of tuberculosis, and death. Our study provides the most comprehensive report on relevant outcomes to date and reports on adverse events. Given the potential for benefit of nutritional intervention, further studies on the role of whole food are warranted.

###### 

 Summary of randomised controlled trials of nutritional interventions and tuberculosis (TB) by year of publication (adapted from Abba^11^) in community based adult patients unless stated otherwise

  Study                             No of patients   Diagnosis        Other criteria          HIV co-infection   Intervention              Risk of bias\*   Outcome measures, significant nutrition effect   Adverse events                              
  --------------------------------- ---------------- ---------------- ----------------------- ------------------ ------------------------- ---------------- ------------------------------------------------ ---------------- ------ ------ ------ ----- -----
  Hanekom, 1997,^21^ South Africa   85               PTB              Hospitalised children   Excluded           Vitamin A                 High             NM                                               NM               NM     No     no     NM    NM
  Morcos, 1998,^23^ Egypt           24               PTB and EPTB     Children                NA                 Vitamin D                 High             NM                                               NM               NM     NM     No     NM    NM
  Karyadi, 2002,^22^ Indonesia      110              Sm+ PTB          ---                     NA                 Vitamin A and Zn          High             NM                                               No               Yes    NM     No     Yes   NM
  Schon, 2003,^24^ Ethiopia         120              Sm+ PTB          ---                     Included           Arginine                  High             NM                                               NM               Yes†   Yes†   Yes†   NM    NM
  Paton, 2004,^19^ Singapore        36               PTB              Hospitalised, wasted    Excluded           High energy and protein   Medium           NM                                               NM               NM     NM     Yes    No    NM
  Range, 2005,^20\ 29^ Tanzania     530              Cu+ or sm+ PTB   ---                     Included           Multivitamins, Zn         Low              No                                               NM               No     NM     Yes    NM    NM
  Perez-Guzman, 2005,^28^ Mexico    21               Cu+ PTB          Hospitalised            Excluded           High cholesterol          High             NM                                               NM               Yes    No     NM     NM    NM
  Nursyam, 2006,^27^ Indonesia      67               Cu+ PTB          Advanced disease        Excluded           Vitamin D                 High             NM                                               NM               Yes    NM     NM     NM    NM
  Seyedrezazadeh, 2006,^30^ Iran    42               Cu+ PTB          ---                     NA                 Vitamin A and Se          High             NM                                               NM               No     NM     No     NM    NM
  Semba, 2007,^31^ Malawi           1148             Sm+ PTB          ---                     Included           Multivitamins             Low              No                                               NM               NM     NM     NM     NM    NM
  Villamor, 2008,^25^ Tanzania      887              Sm+ PTB          ---                     Included           Multivitamins             Medium           No                                               Yes              No     NM     NM     NM    NM
  Wejse, 2009,^26^ Guinea-Bissau    365              PTB and EPTB     ---                     Included           Vitamin D                 Low              No                                               NM               No     No     No     NM    No
  Current study                     270              PTB              ---                     NA                 Whole food                Low              No                                               No               No     No     Yes    NM    Yes

NA = not available; NM = outcome not measured; Qol=quality of life; PTB = pulmonary tuberculosis (sputum smear positive and negative); Sm+ PTB = smear positive; cu+ PTB = culture positive; PTB and EPTB = pulmonary and extrapulmonary TB.

\*According to Cochrane review (excluding current study): low risk = adequate randomisation, blinding and follow-up; medium = one of these inadequate; high = all are inadequate.

†No effect in patients with HIV co-infection.

In this study, the only outcome significantly associated with the intervention was weight gain. Similar findings have been noted in studies in Singapore[@ref19] and in Tanzania[@ref20] but not in others[@ref21] [@ref22] [@ref23] [@ref24] [@ref25]. Specifically, patients who were underweight at baseline were significantly more likely to gain more than 5% during the intensive phase of treatment, an important indicator of improved long term treatment outcome.[@ref8] This suggests that, although a food intervention seems to have little or no effect on treatment adherence and completion rates, this intervention might still be worth considering in patients with tuberculosis who are malnourished at diagnosis. This represents an important incremental step in knowledge and contributes to policy relevant evidence.

Symptoms improve with tuberculosis treatment, and all but one study[@ref24] have failed to show a significant additional improvement with adjunctive nutrition.[@ref21] [@ref26] Early sputum clearance contributes to a decreased period of infectiousness and can have a major influence on tuberculosis control. Our study showed encouraging trends in sputum smear clearance and cure rates in patients with positive sputum smears but was underpowered to examine these outcomes in the subgroup analysis. The findings from other studies are conflicting for this outcome, with one Mexican and two Indonesian studies showing more rapid[@ref22] or more complete[@ref27] [@ref28] sputum smear conversion in the intensive phase, a finding that has so far not been replicated elsewhere.[@ref20] [@ref25] [@ref29] [@ref30] Mortality during tuberculosis treatment is rare in Timor-Leste, and so it is unsurprising that we were unable to show any influence of the intervention on this outcome. Even in areas with high HIV prevalence, where death is more common, no effect has been found.[@ref25] [@ref26] [@ref29] [@ref31]

Study limitations
-----------------

For ethical reasons, we were required to differentiate between patients in the control and intervention groups by spacing their attendance at the clinic: control group in the morning and intervention group at lunchtime. Qualitative data derived from participants in the intervention group suggest that, despite the overwhelming acceptability of the meal, some people expressed shyness about eating at the clinic, while others complained about time inflexibility relating to clinic attendance. This might have been an unanticipated barrier to effective treatment, counteracting any positive effect of food provision and might explain the lower than expected adherence to treatment in the intensive phase. A cluster randomised trial, with a much larger sample size, might have been a more appropriate study design.

The conflict in Dili in the later part of the study clearly affected adherence to treatment in a substantial minority of patients. This led to a lower than expected overall rate of treatment completion. There was, however, no significant difference in the intervention or control groups during this period, so this is unlikely to have explained the negative result.

The randomised controlled trial design minimises confounding and maximises study validity. Our study shows that high quality intervention studies can be conducted successfully even in the most challenging setting. The strict selection of participants, however, might have excluded patients most likely to benefit. Our findings might have been different if we included, for example, those patients who were admitted to albuergues (hostels) for the intensive phase. In Dili, albuergues were designed to accommodate patients with certain characteristics, including high risk of non-adherence. It is also arguable that the true impact of food on treatment outcome and adherence should be measured differently. We lacked the necessary funding and equipment on site to measure potential immunological or biological parameters. Additionally, rather than concentrate on individual treatment outcome or adherence, the impact of a food incentive could be measured in the context of management of a tuberculosis programme. Perhaps the wider influence on the reputation of the clinics might lead to a greater willingness to come for both diagnosis and remain taking treatment.

An expensive intervention
-------------------------

Food provision is an expensive and logistically complex intervention. In this study, the introduction of food incentives involved building works, storage costs, purchase of equipment and consumables, transport, and salary costs, in addition to the actual food provided. When the true costs of these items are taken into account, we estimated the intensive phase costs at \$2-3 (£1.2-1.8, €1.3-1.95) a meal, with a similar weekly cost for the food parcels in the continuation phase. This effectively doubles the cost per patient of tuberculosis treatment. There would need to be substantially stronger evidence of effectiveness of food to make this a cost effective intervention.

Conclusion
----------

This randomised control trial of food incentive to improve treatment outcome was successfully conducted in Timor-Leste. In this setting food supplementation did not significantly improve treatment adherence or treatment outcome. Further studies with a larger sample size and a wider selection of patients in different settings will be required to confirm or refute this finding. Assessment of the impact of food supplementation as a strategy to improve management of tuberculosis programmes more widely and on the biological and immunological determinants of treatment response is also appropriate.

### What is already known on this topic

1.  Tuberculosis remains an important global public health concern

2.  Adequate adherence to treatment is central to tuberculosis control; food incentives are attractive because of the well described link between malnutrition and tuberculosis

3.  Nutritional supplements are being used in tuberculosis programmes in many settings and are popular with patients, though there is unconvincing evidence of direct benefit on a range of clinical outcomes

### What this study adds

1.  In Timor-Leste, food incentives led to modestly higher weight gain in patients with tuberculosis but did not result in a significant improvement in treatment adherence or successful completion of treatment.
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